1887

oa SA Pharmaceutical Journal - The management of attention deficit-hyperactivity disorder in children : evidence-based pharmacy practice

Volume 79, Issue 10
  • ISSN : 2221-5875

 

Abstract

Attention deficit-hyperactivity disorder (ADHD) involves the academic, social and family functioning of the child. Prevalence of the disorder is approximately 5.3% worldwide and occurs mostly in boys. The consequences of ADHD may be substance abuse and other personality disorders, e.g. delinquency. Research has indicated that drug or behavioural interventions may decrease the rate of conduct and personality disorders. Diet therapy may include polyunsaturated fatty acids (fish oil) and iron supplements in children with low ferritin levels, which may improve ADHD symptoms. Drug therapy that involves stimulants (methylphenidate) has been proven to be effective with a good safety profile. However, concerns have been raised about cardiac, psychiatric and growth side-effects. The non-stimulants (atomoxetine) have no abuse potential and reduce insomnia. They also have a better effect on growth in children. Other therapies include antidepressants and α agonists. It is important to treat each patient using individualised therapy. The role of the pharmacist is important to monitor and minimise side-effects.

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/mp_sapj/79/10/EJC129071
2012-11-01
2016-12-09

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error